Literature DB >> 32519352

The Possible Protective Role of α-Synuclein Against Severe Acute Respiratory Syndrome Coronavirus 2 Infections in Patients With Parkinson's Disease.

Sofiane Ait Wahmane1, Abderrahmane Achbani1, Zakaria Ouhaz2, Mohamed Elatiqi1, Ahmed Belmouden1, Mohamed Nejmeddine1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32519352      PMCID: PMC7300655          DOI: 10.1002/mds.28185

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   9.698


× No keyword cloud information.
Parkinson’s disease (PD) is a multisystem disease in which both the central nervous system (CNS) and peripheral nervous system (PNS) are affected. It is characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta as the result of abnormal accumulation and aggregation of α‐synuclein (α‐syn) in the form of Lewy bodies and Lewy neurites. α‐Syn plays an important role in the pathogenesis of neurodegenerative diseases and is considered to be the pathological hallmark of PD and Lewy body dementia. α‐Syn is expressed in neurons (both the CNS and PNS) as well as in erythrocytes and most immune cells. Indeed, several studies have shown that α‐syn is upregulated after immune stimulation. , , Recent reports have shown significant deficiency in T cell development in α‐syn knock‐out mice, which implicates α‐syn in both the development of B‐lymphocytes and in regulation of T cell phenotypes and function. It has multiple immunomodulatory functions, which can promote disease pathogenicity and also offer protection against proinflammatory responses. In addition, it has been shown that α‐syn can also facilitate immune reactions against infections. Moreover, yet little is known about the innate neuron‐specific inhibitors of viral infections in the CNS. Neuronal expression of α‐syn restricts the replication of RNA viruses and protects mice from virus‐induced neuronal injury. By contrast, in the absence of α‐syn, endoplasmic reticulum stress signaling was significantly altered in mice contaminated by neurotrophic RNA viruses, such as West Nile virus and Venezuelan equine encephalitis. This supports the hypothesis that α‐syn may play an important role in immune defense responses. In addition, it has been hypothesized that the α‐syn inhibits viral neuroinvasion from the PNS to the CNS. Microglia are the resident immune cells of the brain; they play a major role in the neuroinfilammatory process with a high phagocytic capacity. It has been shown that a reduction of the α‐syn expression level in microglia highly increases their response to lipopolysaccharides, whereas it decreases their phagocytic ability. This is a consequence of overactivation of phospholipase D2 and cyclooxygenase‐2, which suggests that α‐syn is implicated in lipid‐mediated signaling by microglia. Moreover, α‐syn may be an activating extracellular ligand for microglia. This supports the findings mentioned previously in relation to its neuroprotective effect. Coronavirus 2019 (COVID‐19) can infect neurons and cause disease. It has been shown that it induces neurological diseases such as polyneuropathy, encephalitis, aortic ischemic stroke, and other neurological diseases. , Neurological manifestations of COVID‐19 infection have been classified into 2 categories: CNS and PNS manifestations. CNS symptoms include dizziness, headache, impaired consciousness, acute cerebrovascular disease, ataxia, and epilepsy. However, PNS symptoms are less severe and include hyposmia, hypoplasia, neuralgia, and hypogeusia. Taken together, the evidence noted previously suggests that the overexpression of α‐syn in patients suffering from PD might prevent neuroinvasion by the coronavirus, possibly by inhibiting the spread of the virus from the PNS to the CNS. Consistent with this hypothesis, a retrospective cohort study conducted in Japan showed that patients with parkinsonism hospitalized for pneumonia had a lower rate of in‐hospital mortality. This hypothesis can be confirmed by using a large cohort of patients with PD experiencing a severe acute respiratory syndrome attributed to COVID‐19 infection.

Author Roles

(1) Research Project: A. Conception, B. Organization, C. Execution; (2) Statistical Analysis: A. Design, B. Execution, C. Review and Critique; (3) Manuscript: A. Writing of the First Draft, B. Review and Critique. S.A.: 1A, 1B, 1C, 3A, 3B A.A.: 1A, 1B, 1C, 3A, 3B Z.O.: 1B, 1C, 3A, 3B M.E.: 1B, 3A, 3B A.B.: 1B, 3B M.N.: 1B, 3B
  16 in total

1.  [A core deficit in Parkinson disease?].

Authors:  A Benítez-Burraco; E Herrera; F Cuetos
Journal:  Neurologia       Date:  2015-08-24       Impact factor: 3.109

2.  Influence of Parkinsonism on outcomes of elderly pneumonia patients.

Authors:  Taisuke Jo; Hideo Yasunaga; Nobuaki Michihata; Yusuke Sasabuchi; Wakae Hasegawa; Hideyuki Takeshima; Yukiyo Sakamoto; Hiroki Matsui; Kiyohide Fushimi; Takahide Nagase; Yasuhiro Yamauchi
Journal:  Parkinsonism Relat Disord       Date:  2018-04-03       Impact factor: 4.891

3.  A critical role for alpha-synuclein in development and function of T lymphocytes.

Authors:  Afshin Shameli; Wenbin Xiao; Yan Zheng; Susan Shyu; John Sumodi; Howard J Meyerson; Clifford V Harding; Robert W Maitta
Journal:  Immunobiology       Date:  2015-10-20       Impact factor: 3.144

4.  Alpha-synuclein expression modulates microglial activation phenotype.

Authors:  Susan A Austin; Angela M Floden; Eric J Murphy; Colin K Combs
Journal:  J Neurosci       Date:  2006-10-11       Impact factor: 6.167

5.  Alpha-Synuclein to the Rescue: Immune Cell Recruitment by Alpha-Synuclein during Gastrointestinal Infection.

Authors:  Viviane Labrie; Patrik Brundin
Journal:  J Innate Immun       Date:  2017-09-02       Impact factor: 7.349

Review 6.  Immunology of West Nile Virus Infection and the Role of Alpha-Synuclein as a Viral Restriction Factor.

Authors:  Kelsey E Lesteberg; John David Beckham
Journal:  Viral Immunol       Date:  2018-09-15       Impact factor: 2.257

7.  Microglia and neuroinflammation: a pathological perspective.

Authors:  Wolfgang J Streit; Robert E Mrak; W Sue T Griffin
Journal:  J Neuroinflammation       Date:  2004-07-30       Impact factor: 8.322

8.  Infection with mosquito-borne alphavirus induces selective loss of dopaminergic neurons, neuroinflammation and widespread protein aggregation.

Authors:  Collin M Bantle; Aaron T Phillips; Richard J Smeyne; Savannah M Rocha; Ken E Olson; Ronald B Tjalkens
Journal:  NPJ Parkinsons Dis       Date:  2019-09-13

Review 9.  Impact of SARS-CoV-2 infection on neurodegenerative and neuropsychiatric diseases: a delayed pandemic?

Authors:  P J Serrano-Castro; G Estivill-Torrús; P Cabezudo-García; J A Reyes-Bueno; N Ciano Petersen; M J Aguilar-Castillo; J Suárez-Pérez; M D Jiménez-Hernández; M Á Moya-Molina; B Oliver-Martos; C Arrabal-Gómez; F Rodríguez de Fonseca
Journal:  Neurologia (Engl Ed)       Date:  2020-04-17

10.  Potential neurological symptoms of COVID-19.

Authors:  Hai-Yang Wang; Xue-Lin Li; Zhong-Rui Yan; Xiao-Pei Sun; Jie Han; Bing-Wei Zhang
Journal:  Ther Adv Neurol Disord       Date:  2020-03-28       Impact factor: 6.570

View more
  13 in total

Review 1.  COVID-19 and Parkinson's Disease: Possible Links in Pathology and Therapeutics.

Authors:  Shubhangini Tiwari; Neelam Yadav; Sarika Singh
Journal:  Neurotox Res       Date:  2022-07-13       Impact factor: 3.978

2.  Effect of an Amyloidogenic SARS-COV-2 Protein Fragment on α-Synuclein Monomers and Fibrils.

Authors:  Asis K Jana; Chance W Lander; Andrew D Chesney; Ulrich H E Hansmann
Journal:  J Phys Chem B       Date:  2022-05-17       Impact factor: 3.466

3.  Prevalence and outcomes of Covid-19 in Parkinson's disease: Acute settings and hospital.

Authors:  Conor Fearon; Alfonso Fasano
Journal:  Int Rev Neurobiol       Date:  2022-04-20       Impact factor: 4.280

Review 4.  Possible Link between SARS-CoV-2 Infection and Parkinson's Disease: The Role of Toll-Like Receptor 4.

Authors:  Carmela Conte
Journal:  Int J Mol Sci       Date:  2021-07-01       Impact factor: 5.923

5.  COVID-19 and the brain: impact on nuclear medicine in neurology.

Authors:  Silvia Morbelli; Ozgul Ekmekcioglu; Henryk Barthel; Nathalie L Albert; Ronald Boellaard; Diego Cecchin; Eric Guedj; Adriaan A Lammertsma; Ian Law; Ivan Penuelas; Franck Semah; Tatjana Traub-Weidinger; Elsmarieke van de Giessen; Andrea Varrone; Valentina Garibotto
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-10       Impact factor: 9.236

Review 6.  COVID-19 and neurological disorders: are neurodegenerative or neuroimmunological diseases more vulnerable?

Authors:  Luigi Ferini-Strambi; Maria Salsone
Journal:  J Neurol       Date:  2020-07-21       Impact factor: 4.849

Review 7.  The Intersection of Parkinson's Disease, Viral Infections, and COVID-19.

Authors:  Benjamin Rosen; Alberim Kurtishi; Gonzalo R Vazquez-Jimenez; Simon Geir Møller
Journal:  Mol Neurobiol       Date:  2021-05-25       Impact factor: 5.590

Review 8.  Covid-19 and Parkinson's disease: an overview.

Authors:  S M Cartella; C Terranova; V Rizzo; A Quartarone; P Girlanda
Journal:  J Neurol       Date:  2021-07-27       Impact factor: 4.849

9.  Clinical characterization and therapeutic targets of vitamin A in patients with hepatocholangiocarcinoma and coronavirus disease.

Authors:  Xiao Liang; Rui Zhou; Yu Li; Lu Yang; Min Su; Keng Po Lai
Journal:  Aging (Albany NY)       Date:  2021-06-27       Impact factor: 5.682

Review 10.  Can SARS-CoV-2 Infection Lead to Neurodegeneration and Parkinson's Disease?

Authors:  Lea Krey; Meret Koroni Huber; Günter U Höglinger; Florian Wegner
Journal:  Brain Sci       Date:  2021-12-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.